May 11, 2026 11:13 am (IST)
Follow us:
Dahej plant of Torrent Pharma receives USFDA approval
Ahmedabad/Mumbai, Mar 18 (IBNS) Torrent Pharma, a leading Indian pharma company, informed on Friday that it has obtained the Establishment Inspection Report from the U.S. Food and Drug Administration (USFDA) for its plant located at Dahej SEZ, Gujarat.
The company had set up the plant mainly to cater to the regulated international markets such as US, Germany, Brazil, etc.
Prior to the US approval, the plant had received approval from EU Germany.
The Dahej plant is spread across 70 acres of land with a built up area of about 97000 sq meter. Phase 1 has an installed capacity to manufacture 7,500 million tablets/capsules and 25 MT API per annum.
The company has said that construction of Phase 2 will commence soon. After commission, the total capacity will increase to manufacture of 14,000 million tablets/capsules and 80 MT API per annum.
In their filing with the National Stock Exchang, the company has said that with the approval of the Dahej plant, three of its five plants have received USFDA approval.
The other two plants are located at Indrad (Gujarat) and Pithampur, Indore (Madhya Pradesh).
The company's share price moved up during trading hours on Friday following the news of the approval
Torrent Pharma is a flagship company of the Torrent Group.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Sensex crashes over 1,000 points as West Asia tensions rattle markets, oil prices surge
Mon, May 11 2026
AI takes over? Cloudflare cuts 1,100 jobs as AI surges
Fri, May 08 2026
Profit jumps 30%! Aditya Birla Capital posts strong Q4 FY26 results
Fri, May 08 2026
Claim Settlement Ratio Explained: How It Affects Your Policy
Thu, May 07 2026
Amidst rising input costs, manufacturing growth remains positive: FICCI Manufacturing Survey
Wed, May 06 2026
Nissan Motor India launches nationwide AC Check-up Camp to help customers stay summer-ready
Wed, May 06 2026